ClinicalTrials.govpublic full text
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
parkinson's disease, levodopa, end of dose wearing off, off time, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 875222
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.